Search  in | Advanced
   Print  

2008 West Nile Virus Biovigilance Network

The West Nile Virus (WNV) Biovigilance Network collates data on donors (of blood, tissue and hematopoietic progenitor cells) with suspected WNV infection in the United States and Canada. Data for the calendar year 2008 were collected from donor screening tests performed by nucleic acid amplification testing (NAT). The data were reported to the AABB site by facilities responsible for testing virtually all blood donations in the United States and Canada. The reports provided here illustrate the geographic and temporal distribution of WNV infection as reflected by presumed viremic donors (PVDs) during the 2008 peak season.
 
This section includes a map showing locations where these PVDs have been identified; a bar graph identifying total PVDs by week collected; and a password-protected section for reviewing reports of WNV activity.

2008 U.S./Canada Map: Suspected Cases by Postal Code
2008 WNV Presumed Viremic Donations by Week

Background
2008 WNV Blood Donor Data Reports  (password-protected area)

Resources:
Association Bulletin #08-03 - West Nile Virus – Revised Recommendations for Triggering Individual Donation Nucleic Acid Testing and Use of Communication Plans (member content)
2009 West Nile Virus Biovigilance Network
2007 West Nile Virus Biovigilance Network 
2006 West Nile Virus Biovigilance Network

Quick Links:
CDC Maps of WNV Activity
CDC FAQ on WNV

2008 U.S./Canada Map: Suspected Cases by Postal Code (updated 3/5/09)
Alaska and Hawaii

 

This map shows presumed viremic donations (PVDs) by residential postal code of the donor in the United States and Canada. To be defined as a PVD, the sample must meet one of the following criteria: 1) a reactive sample that is repeatable by ID NAT, i.e., repeatable NAT reactivity using the same screening test, analogous to repeat reactivity in serology; or 2) reactivity in the Procleix assay that has a signal-to-cutoff ratio exceeding or equal to 17. Participating facilities report PVDs as they occur based on test results.

Top

2008 WNV Presumed Viremic Donations by Week (updated 3/5/09)

This bar graph identifies the total number of presumed viremic donations (PVDs) by week of donation as identified through NAT. PVDs are defined as: 1) a reactive sample that is repeatable by ID NAT, i.e., repeatable NAT reactivity using the same screening test, analogous to repeat reactivity in serology; or 2) reactivity in the Procleix assay that has a signal-to-cutoff ratio exceeding or equal to 17. PVDs are reported by facilities as they occur based on the test results.

Top 

Background

This electronic data network, initiated in 2006,  was developed by the WNV Task Force. The task force includes representatives from AABB, the Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, the Food and Drug Administration (FDA), U.S. Department of Defense, American Red Cross, America’s Blood Centers, Canadian Blood Services and United Blood Services. The WNV Task Force accepted this charge as part of AABB’s mission to improve patient safety with respect to transfusion medicine and, in particular, to fulfill its stated goal of taking a leadership role in creating a biovigilance system in the United States.

This tool is intended to support and enhance an identification and tracking initiative that AABB had developed in partnership with FDA and CDC when WNV first became a public health concern. This resource is not intended to supplant or replace public health agency data collection, or to predict the occurrence, frequency or location of WNV, but rather to support public health agencies, blood collection facilities and transfusion services.

The data posted on this Web site are provided by third parties and are not verified by AABB.  Accordingly, AABB makes no guarantee or promise that the data are current, valid, or accurate. No content on this site is intended to constitute professional advice, whether medical, legal or otherwise. AABB expressly disclaims any liability or loss that may arise either directly or indirectly from relying on the information, services or other material on this site.

Reporting facilities that are HIPAA-compliant should determine what, if any, donor/patient information may be reported and should consider reporting only donors’ states of residence, not donor zip codes. AABB is not responsible for reporting facilities’ compliance with federal, state or local laws or regulations.

Top


2008 WNV Blood Donor Data Reports

WNV Blood Donor Data Reports  (password-protected)

Support

WNV Biovigilance Network Training Guide (PDF)
WNV Biovigilance Network FAQ

For technical support or for more information, call +1.800.793.9376 (weekdays between 8:30 am and 5:00 pm ET).
 
For optimal viewing, use Microsoft Internet Explorer® 6.0 or later and set your screen resolution to 1024 x 768.

Top

Last modified on 4/15/2009 8:57:22 AM
What's New!
AABB Weekly Report - June 26, 2009
Details
FDA Liaison Meeting – 5/29/09
Details
AABB Launches Facebook Fan Page
Details
The Proposed 4th edition of Standards for Cellular Therapy Product Services
Details
National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion
Details
Association Bulletin #09-03 - Influenza A (H1N1) of Porcine Origin – Update
Details
Association Bulletin #09-02 - Swine Influenza H1N1
Details
Nominees for the 2009-10 AABB Board of Directors
Details
AABB’s Accreditation Program Granted Accreditation by the International Society for Quality in Health Care
Details
AABB Patient and Donor Safety Center Named a Patient Safety Organization by Department of Health and Human Services
Details
List of AABB-Accredited Facilities with Approved Variances for ISBT 128
Details